Outcome of children with hereditary tyrosinaemia following newborn screening

Archives of Disease in Childhood

Volumn 100, Issue 8, 2015, Pages 738-741

  McKiernan, P J ^a   Preece, Mary Anne ^a   Chakrapani, Anupam ^a  

^a BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; NITISINONE; TYROSINE; ALPHA FETOPROTEIN; CYCLOHEXANONE DERIVATIVE; ENZYME INHIBITOR; FUMARYLACETOACETASE; HYDROLASE; NITROBENZOIC ACID DERIVATIVE;

ACUTE LIVER FAILURE; ARTICLE; BLOOD CLOTTING DISORDER; CHRONIC LIVER DISEASE; CLINICAL ARTICLE; DECOMPENSATED LIVER CIRRHOSIS; DIET RESTRICTION; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; LEARNING; LIVER FAILURE; LIVER FUNCTION TEST; LIVER TRANSPLANTATION; MALE; METABOLIC REGULATION; NEWBORN; NEWBORN SCREENING; PREMATURITY; PRIORITY JOURNAL; SIBLING; TONIC CLONIC SEIZURE; TREATMENT DURATION; TREATMENT OUTCOME; TYROSINEMIA; BLOOD; GENETICS; GENOTYPE; METABOLISM; MUTATION; PROTHROMBIN TIME; TYROSINEMIAS;

ALPHA-FETOPROTEINS; CYCLOHEXANONES; ENZYME INHIBITORS; FEMALE; GENOTYPE; HUMANS; HYDROLASES; INFANT, NEWBORN; MALE; MUTATION; NEONATAL SCREENING; NITROBENZOATES; PROTHROMBIN TIME; TREATMENT OUTCOME; TYROSINEMIAS;

EID: 84937163325     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/archdischild-2014-306886     Document Type: Article

References (22)

1. McKiernan PJ. Nitisinone for the treatment of hereditary tyrosinemia type I. Expert Opin Orphan Drugs 2013;1:491-7.
2. de Laet C, Dionisi-Vici C, Leonard JV, et al. Recommendations for the management of tyrosinaemia type 1. Orphanet J Rare Dis 2013;8:8.
3. Mayorandan S, Meyer U, Gokcay G, et al. Cross-sectional study of 168 patients with hepatorenal tyrosinaemia and implications for clinical practice. Orphanet J Rare Dis 2014;9:107.
4. Holme E, Lindstedt S. Nontransplant treatment of tyrosinemia. Clin Liver Dis 2000;4:805-14.
5. van Spronsen FJ, Bijleveld CM, van Maldegem BT, et al. Hepatocellular carcinoma in hereditary tyrosinemia type I despite 2-(2 nitro-4-3 trifluoro-methylbenzoyl)-1, 3-cyclohexanedione treatment. J Pediatr Gastroenterol Nutr 2005;40:90-3.
6. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000555/WC500049195.pdf. 1-1-2013. Ref Type: Internet Communication
7. Weinberg AG, Mize CE, Worthen HG. The occurrence of hepatoma in the chronic form of hereditary tyrosinemia. J Pediatr 1976;88:434-8.
8. van Spronsen FJ, Thomasse Y, Smit GP, et al. Hereditary tyrosinemia type I: a new clinical classification with difference in prognosis on dietary treatment. Hepatology 1994;20:1187-91.
9. Larochelle J, Alvarez F, Bussieres JF, et al. Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Quebec. Mol Genet Metab 2012;107:49-54.
10. Baumann U, Duhme V, Auth MK, et al. Lectin-reactive alpha-fetoprotein in patients with tyrosinemia type I and hepatocellular carcinoma. J Pediatr Gastroenterol Nutr 2006;43:77-82.
11. Dehner LP, Snover DC, Sharp HL, et al. Hereditary tyrosinemia type I (chronic form): pathologic findings in the liver. Hum Pathol 1989;20:149-58.
12. Mitchell GA, Grompe M, Lambert M, et al. Hypertyrosinemia. In: Scriver CRBALSWSVD, ed. The Metabolic and molecular bases of inherited disease. New York: McGraw-Hill, 2001:1777-805.
13. Hostetter MK, Levy HL, Winter HS, et al. Evidence for liver disease preceding amino acid abnormalities in hereditary tyrosinemia. N Engl J Med 1983;308:1265-7.
14. De Laet C, Munoz VT, Jaeken J, et al. Neuropsychological outcome of NTBC-treated patients with tyrosinaemia type 1. Dev Med Child Neurol 2011;53:962-4.
15. Thimm E, Richter-Werkle R, Kamp G, et al. Neurocognitive outcome in patients with hypertyrosinemia type I after long-term treatment with NTBC. J Inherit Metab Dis 2012;35:263-8.
16. Masurel-Paulet A, Poggi-Bach J, Rolland MO, et al. NTBC treatment in tyrosinaemia type I: long-term outcome in French patients. J Inherit Metab Dis 2008;31:81-7.
17. Bendadi F, de Koning TJ, Visser G, et al. Impaired cognitive functioning in patients with tyrosinemia type I receiving nitisinone. J Pediatr 2014;164:398-401.
18. Pandor A, Eastham J, Beverley C, et al. Clinical effectiveness and cost-effectiveness of neonatal screening for inborn errors of metabolism using tandem mass spectrometry: a systematic review. Health Technol Assess 2004;8:iii, 1-iii121.
19. la Marca G, Malvagia S, Materazzi S, et al. LC-MS/MS method for simultaneous determination on a dried blood spot of multiple analytes relevant for treatment monitoring in patients with tyrosinemia type I. Anal Chem 2012;84:1184-8.
20. Turgeon C, Magera MJ, Allard P, et al. Combined newborn screening for succinylacetone, amino acids, and acylcarnitines in dried blood spots. Clin Chem 2008;54:657-64.
21. Morrissey MA, Sunny S, Fahim A, et al. Newborn screening for Tyr-I: two years' experience of the New York State program. Mol Genet Metab 2011;103:191-2.
22. Hutchesson AC, Hall SK, Preece MA, et al. Screening for tyrosinaemia type I. Arch Dis Child Fetal Neonatal Ed 1996;74:F191-4.